Literature DB >> 18830869

Intravenous vitamin C in the treatment of post-laser hyperpigmentation for melasma: a short report.

Georgia Siow Kiang Lee1.   

Abstract

Melasma is difficult to treat. Vitamin C, topical and by iontophoresis, has been shown to be useful. When lasers are used, there is a significant incidence of post-laser hyperpigmentation. There is no single established treatment for the latter. The case history of a 51-year-old Chinese woman is presented. Intravenous vitamin C appears to be useful in treating this complication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18830869      PMCID: PMC2645136          DOI: 10.1080/14764170802187193

Source DB:  PubMed          Journal:  J Cosmet Laser Ther        ISSN: 1476-4172            Impact factor:   2.247


Introduction

Melasma is often difficult to treat. It is more common in females and is associated with sun exposure, pregnancy and contraceptive pill use. When severe, it can be socially embarrassing for patients. Treatment involves broad-spectrum (UVA+UVB) sunscreen and topical hydroquinone. Other lightening agents include retinoic acid (tretinoin) and azelaic acid. Combination therapies such as hydroquinone, tretinoin, and corticosteroids are thought to be superior to monotherapy. Lasers are used in cases of refractory melasma, but the incidence of post-inflammatory hyperpigmentation is high (1), and more so in Asian populations with higher epidermal melanin content (2). When it occurs, treatment with hydroquinone cream with other depigmentating agents speeds its resolution (3), which can take several months. Intravenous vitamin use to treat this distressing complication is described.

Case report

A 51-year-old postmenopausal Chinese woman presented with significant melasma of many years duration with no response from sunblock, chemical peeling and depigmentation cream obtained from another practitioner (Figure 1). Depigmentation cream (retinoic acid 0.025%, hydroquinoine 5% and triaminolone 0.1%) was applied to the affected area at night. Concurrent vitamin C iontophoresis was started with some improvement after seven sessions. However, she developed excessive dryness from the treatment (Figure 2). A course of monthly Q-switched 1064 nm Nd:YAG laser treatment with settings at spot size 7 mm and 2.1 J/cm2 was added to the vitamin C iontophoresis regime with some improvement in the skin condition initially (Figure 3).
Figure 1

Before treatment with iontophoresis vitamin C.

Figure 2

After seven sessions with iontophoresis vitamin C.

Figure 3

After the first (A), second (B), sixth (C), 10th (D) and 11th (E) laser sessions with iontophoresis vitamin C.

Before treatment with iontophoresis vitamin C. After seven sessions with iontophoresis vitamin C. After the first (A), second (B), sixth (C), 10th (D) and 11th (E) laser sessions with iontophoresis vitamin C. She developed post-laser hyperpigmentation after 11 laser sessions and intravenous vitamin C (7 g) was added after 18 months of therapy. A total of three doses of intravenous vitamin C, 7 g each time, were administered; the first two doses were given a week apart, 1 month after the laser treatment which caused her significant hyperpigmentation. She returned for follow-up after a 5-month lapse due to work commitments with no other treatments prescribed in the interim, when a 12th session of laser treatment was performed together with a third concurrent dose of intravenous vitamin C (7g). She had significant improvement in skin pigmentation after this last session which is lasting without any post-laser hyperpigmentation noted (Figure 4).
Figure 4

After the 12th laser session with three sessions of intravenous vitamin C.

After the 12th laser session with three sessions of intravenous vitamin C.

Discussion

Post-laser hyperpigmentation is a significant complication and requires considerable preoperative counseling and effort in management (4). Patients with darker skin tones are at a higher inherent risk of side effects from laser surgery. Although advances in laser technology and individualized treatment parameters have reduced the incidence of undesirable postoperative sequelae, these risks can never be completely eliminated. Hence, thorough preoperative preparation and education regarding the risks of cutaneous laser therapy is essential (5). The Q-switched (Qs) Nd:YAG laser is specially indicated in targeting melanin for the treatment of melasma, although it is associated with a significant incidence of post-inflammatory pigmentation. This is especially distressing to the patient if the indication for laser therapy is localized hyperpigmentation in the first place. There is considerable literature on the topic of intravenous vitamin C, a strong anti-oxidant, which plays an important role in maintaining physiological states. In dermatology, vitamin C is used in the treatment of various skin problems such as depigmentation of hyperpigmented spots (6). Melanogenesis is caused by enzymatic conversion of tyrosine to melanin pigments. As ascorbic acid has the ability to inhibit peroxidase and thus melanin synthesis, the University of Taiwan has proposed investigating the use of intravenous vitamin C in improving skin hyperpigmentation in chronic hemo-dialysis patients. However, vitamin C has limited stability and permeability (7). Improving vitamin C delivery by iontophoresis appears useful (8). Padayatty et al. studied vitamin C pharmacokinetics, comparing oral and intravenous routes in 17 healthy hospitalized volunteers. They concluded that only intravenous vitamin C produces high plasma concentrations (9). Hence, it is logical to postulate that intravenous vitamin C may be effective in the treatment of post-laser hyperpigmentation. The use of high-dose vitamin C in curing a variety of conditions such as the common cold to cancer is quite controversial. However, the debate remains such that the FDA is currently sponsoring a clinical trial of intravenous vitamin C in cancer. There is little evidence that ascorbate, as all naturally occurring substances, has any harmful effects, except in individuals with a rare genetic predisposition. A theoretical side effect could be on oxalate metabolism, which predisposes to kidney stones (10). Animal experiments indicate there is little risk of overdosage in the regimen used clinically. There is also a tendency towards hypoglycemia during intravenous administration.

Conclusion

This case illustrates the typical problems associated with treating melasma. This includes prolonged courses of therapy using multiple modalities. Vitamin C is useful as evidenced by the response to iontophoresis. But with the added complication of post-laser hyperpigmentation, it appears that intravenous vitamin C in a moderate dose did offer a significant benefit in this patient. Further experience is required with vitamin C when administered by the intravenous route.
  10 in total

1.  Post laser hyperpigmentation and occupational ultraviolet radiation exposure.

Authors:  D A Munnoch; C M Gorst; K Hancock
Journal:  Br J Plast Surg       Date:  2000-04

2.  Erbium:YAG laser resurfacing for refractory melasma.

Authors:  R M Manaloto; T Alster
Journal:  Dermatol Surg       Date:  1999-02       Impact factor: 3.398

Review 3.  Effective and safe use of lasers, light sources, and radiofrequency devices in the clinical management of Asian patients with selected dermatoses.

Authors:  Henry H L Chan
Journal:  Lasers Surg Med       Date:  2005-09       Impact factor: 4.025

4.  A new lipophilic pro-vitamin C, tetra-isopalmitoyl ascorbic acid (VC-IP), prevents UV-induced skin pigmentation through its anti-oxidative properties.

Authors:  Yasunobu Ochiai; Satoko Kaburagi; Kei Obayashi; Nobuyuki Ujiie; Satoru Hashimoto; Yuri Okano; Hitoshi Masaki; Masamitsu Ichihashi; Hiromu Sakurai
Journal:  J Dermatol Sci       Date:  2006-08-28       Impact factor: 4.563

Review 5.  The use of hydroquinone with facial laser resurfacing.

Authors:  M P Goldman
Journal:  J Cutan Laser Ther       Date:  2000-06

6.  Ascorbate increases human oxaluria and kidney stone risk.

Authors:  Linda K Massey; Michael Liebman; Susan A Kynast-Gales
Journal:  J Nutr       Date:  2005-07       Impact factor: 4.798

7.  A randomized, double-blind, placebo-controlled trial of vitamin C iontophoresis in melasma.

Authors:  Chang-Hun Huh; Koo-Il Seo; Je-Young Park; Jeong-Gu Lim; Hee-Chul Eun; Kyung-Chan Park
Journal:  Dermatology       Date:  2003       Impact factor: 5.366

Review 8.  Laser surgery in dark skin.

Authors:  Nirali Bhatt; Tina S Alster
Journal:  Dermatol Surg       Date:  2008-02       Impact factor: 3.398

9.  Vitamin C pharmacokinetics: implications for oral and intravenous use.

Authors:  Sebastian J Padayatty; He Sun; Yaohui Wang; Hugh D Riordan; Stephen M Hewitt; Arie Katz; Robert A Wesley; Mark Levine
Journal:  Ann Intern Med       Date:  2004-04-06       Impact factor: 25.391

10.  A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma.

Authors:  Liliana Elizabeth Espinal-Perez; Benjamin Moncada; Juan Pablo Castanedo-Cazares
Journal:  Int J Dermatol       Date:  2004-08       Impact factor: 2.736

  10 in total
  2 in total

Review 1.  The effect of Vitamin C on melanin pigmentation - A systematic review.

Authors:  Rizwan M Sanadi; Revati S Deshmukh
Journal:  J Oral Maxillofac Pathol       Date:  2020-09-09

2.  Efficacy of intradermal injection of tranexamic acid and ascorbic acid versus tranexamic acid and placebo in the treatment of melasma: A split-face comparative trial.

Authors:  Nader Pazyar; Seyedeh Nasrin Molavi; Parisa Hosseinpour; Maryam Hadibarhaghtalab; Seyedeh Yasamin Parvar; Motahareh Babazadeh Dezfuly
Journal:  Health Sci Rep       Date:  2022-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.